CEREVEL THERAPEUTICS HLDNG I's ticker is CERE and the CUSIP is 15678U128. A total of 86 filers reported holding CEREVEL THERAPEUTICS HLDNG I in Q2 2021. The put-call ratio across all filers is 0.25 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,404,920 | -58.8% | 476,634 | -40.0% | 0.12% | -59.3% |
| Q2 2023 | $25,270,475 | +69.5% | 794,919 | +30.0% | 0.30% | +47.8% |
| Q1 2023 | $14,911,217 | +1.8% | 611,366 | +31.6% | 0.20% | +3.6% |
| Q4 2022 | $14,647,428 | -3.4% | 464,408 | -13.4% | 0.20% | -7.5% |
| Q3 2022 | $15,158,000 | +124.4% | 536,385 | +109.9% | 0.21% | +103.8% |
| Q2 2022 | $6,756,000 | -46.7% | 255,533 | -29.4% | 0.10% | -49.5% |
| Q1 2022 | $12,665,000 | +64.6% | 361,753 | +52.4% | 0.21% | +87.3% |
| Q4 2021 | $7,694,000 | +33.5% | 237,326 | +21.5% | 0.11% | +17.0% |
| Q3 2021 | $5,762,000 | +56.5% | 195,331 | +35.9% | 0.09% | +36.2% |
| Q2 2021 | $3,682,000 | -31.8% | 143,712 | -63.4% | 0.07% | -42.5% |
| Q1 2021 | $5,395,000 | – | 392,910 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BAIN CAPITAL INVESTORS LLC | 60,632,356 | $1,965,701,000 | 23.51% |
| Affinity Asset Advisors, LLC | 225,000 | $7,295,000 | 2.65% |
| Perceptive Advisors | 10,173,454 | $329,822,000 | 2.54% |
| Artal Group S.A. | 1,500,000 | $48,630,000 | 1.32% |
| Rock Springs Capital Management LP | 1,648,435 | $53,442,000 | 1.24% |
| RTW INVESTMENTS, LP | 666,666 | $21,613,000 | 0.32% |
| BOULDER HILL CAPITAL MANAGEMENT LP | 8,900 | $289,000 | 0.28% |
| EAM Investors, LLC | 39,907 | $1,294,000 | 0.21% |
| FEDERATED HERMES, INC. | 3,113,333 | $100,934,000 | 0.19% |
| Alkeon Capital Management | 1,909,035 | $61,891,000 | 0.12% |